Trial · NCT07902518
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
NCT07902518, Not applicable, Recruiting, Ciusss de L'Est de l'Île de Montréal
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations. Trials, record NCT07902518. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902518
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
- NCT number
- NCT07902518
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Conditions
- Auditory Verbal Hallucinations, Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Interventions
- Theta-Burst Transcranial Magnetic Stimulation (TBS)
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Auditory Hallucination Severity (PSYRATS-AH) | Baseline, approximately 1 week after treatment, and 1-month follow-up | Severity of auditory verbal hallucinations will be assessed using the auditory hallucinations subscale of the Psychotic Symptom Rating Scales (PSYRATS-AH). This 11-item clinician-rated scale measures different characteristics of auditory hallucinations, including frequency, duration, distress, and disruption to daily life. Total scores range from 0 to 44, with higher scores indicating greater hallucination severity. |
| Secondary | Change in Overall Psychotic Symptom Severity (PANSS) | Baseline, approximately 1 week after treatment, and 1-month follow-up | Psychotic symptom severity will be assessed using the Positive and Negative Syndrome Scale (PANSS). The scale includes 30 clinician-rated items evaluating positive symptoms, negative symptoms, and general psychopathology. Total scores range from 30 to 210, with higher scores indicating greater symptom severity. |
| Secondary | Change in Depressive Symptoms (MADRS) | Baseline, approximately 1 week after treatment, and 1-month follow-up | Depressive symptoms will be assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), a 10-item clinician-rated measure of depression severity. Total scores range from 0 to 60, with higher scores indicating more severe depressive symptoms. |
| Secondary | Change in Subjective Cognitive Difficulties (SSTICS) | Baseline, approximately 1 week after treatment, and 1-month follow-up | Subjective cognitive difficulties will be assessed using the Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS), a self-report questionnaire measuring perceived cognitive difficulties in everyday life. Higher scores indicate greater subjective cognitive difficulties. |
| Secondary | Change in Insight into Illness (PANSS G12) | Baseline, approximately 1 week after treatment, and 1-month follow-up | Insight into illness will be assessed using item G12 (Lack of Judgment and Insight) of the Positive and Negative Syndrome Scale (PANSS). Scores range from 1 to 7, with higher scores indicating greater impairment in insight. |
| Secondary | Change in Functional Impairment (Sheehan Disability Scale) | Baseline, approximately 1 week after treatment, and 1-month follow-up | Functional impairment will be assessed using the Sheehan Disability Scale (SDS), a self-report measure evaluating impairment in work or school, social life, and family life. Each domain is scored from 0 to 10, with higher scores indicating greater impairment. The total score ranges from 0 to 30. |
| Other | Tolerability of Theta-Burst Stimulation | Throughout the 2-week treatment period and up to the 1-month follow-up | Treatment tolerability will be evaluated by documenting adverse effects reported during treatment sessions and follow-up assessments, including their nature and frequency. |
| Other | Treatment Completion Rate | Throughout the 2-week treatment period | Treatment completion will be assessed by recording the number of theta-burst stimulation sessions completed by each participant out of the 20 planned sessions. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902518
GET https://conductscience.org/api/trials/v1/NCT07902518/registered